BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment
Status:
Completed
Trial end date:
2016-07-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish an optimal treatment duration and tolerable
cumulative dose for BP-C1 in the treatment of metastatic breast cancer patients who had
previously undergone at least three lines of chemotherapy.